Co-Inventors
Nattermann, Una
King, Neil
Kanekiyo, Masaru
Lederhofer, Julia
Graham, Barney
Baker, David
Research Products
Research Equipment
Antibodies
Engineered Influenza Neuraminidase Antigens represent a cutting-edge approach to revolutionize Influenza vaccine development. This technology harnesses the sequences of neuraminidase (NA) proteins, pivotal components of the Influenza virus, to create stabilized tetramers for multiple NA subtypes. By identifying specific mutations, the technology enables the control of NA protein conformations, particularly closed states, which significantly enhances their stability. These stabilized NA structures have immense potential as vaccine antigens, available either in soluble forms or presented on scaffolds, providing versatility in Influenza vaccine design. Overall, this breakthrough technology promises to elevate the efficacy and design of Influenza vaccines, ultimately contributing to better public health outcomes.
Commercial Applications
Engineered Influenza Neuraminidase Antigens offer versatile potential applications. They are poised to play a pivotal role in the development of more effective Influenza vaccines, ensuring robust protection against a range of Influenza strains, including those prone to rapid mutation. Additionally, these stabilized NA antigens can find utility in research and diagnostics, serving as valuable tools for studying Influenza virus biology and enhancing the accuracy of diagnostic assays. Moreover, their adaptability in soluble or scaffold-presented forms opens avenues for innovative drug delivery systems and targeted therapeutic applications.
Competitive Advantages
Engineered Influenza Neuraminidase Antigens offer a competitive edge through their capacity to stabilize and control neuraminidase (NA) proteins, a crucial component in Influenza vaccines. This technology ensures consistent NA protein stability, crucial for vaccine production. Its unique ability to manipulate NA protein conformations, favoring closed states, provides a novel approach to stabilization. Moreover, the versatility of these stabilized NA structures, available in soluble or scaffold-presented forms, offers flexibility in vaccine design, catering to various Influenza strains and subtypes.
